Eli Lilly Reports Strong Initial Traction for Foundayo Weight Loss Pill

Eli Lilly has seen a strong start for its newly FDA-approved weight loss pill, Foundayo, with more than 20,000 patients beginning treatment within the first few weeks of its market debut. CEO Dave Ricks noted that approximately 1,000 people are starting the medication daily, signaling healthy organic demand for the oral alternative. Unlike previous launches such as Zepbound, which leveraged existing brand recognition from the diabetes drug Mounjaro, Foundayo is being established as a new brand. Ricks emphasized that building awareness among doctors and patients will be a gradual process, noting that the drug's trajectory will play out over quarters rather than days. Data suggests the oral format is expanding the reachable market, as over 80% of Foundayo users are new to GLP-1 medications. This expansion comes as Eli Lilly continues to see explosive growth in its injectable portfolio; first-quarter sales for Mounjaro and Zepbound surged by 125% and 80%, respectively. Eli Lilly currently maintains a commanding lead in the U.S. obesity and diabetes drug market with a 60.1% share, compared to 39.4% for its primary competitor, Novo Nordisk. While Foundayo's early numbers were not included in the recent Q1 financial results due to the timing of the launch, the initial adoption rates support the company's goal of maintaining market dominance.